Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Apiam Animal Health Ltd. ( (AU:AHX) ) has issued an announcement.
Apiam Animal Health Ltd. reported modest revenue and earnings growth for FY25, with a 1.4% increase in revenue and a 5.2% rise in EBITDA. The company faced challenges in its Clinical Vet Services segment, notably due to reduced equine revenues and the cessation of dairy cattle exports to China, impacting diagnostic revenues. However, the Intensive Animal Veterinary Services segments, particularly beef feedlot and pigs, showed strong performance with double-digit growth. The company is undergoing a Strategic Reset Program under new Interim Managing Director Bruce Dixon, aiming to improve core operations and shareholder returns. Apiam also divested two underperforming businesses, resulting in an impairment loss of $4.5 million, and received a non-binding indicative proposal from Adamantem Capital to acquire the company.
The most recent analyst rating on (AU:AHX) stock is a Hold with a A$0.88 price target. To see the full list of analyst forecasts on Apiam Animal Health Ltd. stock, see the AU:AHX Stock Forecast page.
More about Apiam Animal Health Ltd.
Apiam Animal Health Ltd. operates in the veterinary services industry, focusing on clinical veterinary services and intensive animal veterinary services, particularly in the beef feedlot and pig segments. The company provides diagnostic services through ACE Laboratories and has a market focus that includes companion animals, mixed animal clinics, and equine services.
Average Trading Volume: 151,629
Technical Sentiment Signal: Buy
Current Market Cap: A$145.3M
Find detailed analytics on AHX stock on TipRanks’ Stock Analysis page.